Moolec Science SA Ordinary Shares (MLEC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Moolec Science SA Ordinary Shares stock (MLEC) is currently trading at $6.66. Moolec Science SA Ordinary Shares PS ratio (Price-to-Sales) is 0.01. Analyst consensus price target for MLEC is $3.00. WallStSmart rates MLEC as Sell.
- MLEC PE ratio analysis and historical PE chart
- MLEC PS ratio (Price-to-Sales) history and trend
- MLEC intrinsic value — DCF, Graham Number, EPV models
- MLEC stock price prediction 2025 2026 2027 2028 2029 2030
- MLEC fair value vs current price
- MLEC insider transactions and insider buying
- Is MLEC undervalued or overvalued?
- Moolec Science SA Ordinary Shares financial analysis — revenue, earnings, cash flow
- MLEC Piotroski F-Score and Altman Z-Score
- MLEC analyst price target and Smart Rating
Moolec Science SA
📊 No data available
Try selecting a different time range
Smart Analysis
Moolec Science SA Ordinary Shares (MLEC) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Moolec Science SA Ordinary Shares (MLEC) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Revenue surging 948.00% year-over-year
Trading at 1.07x book value, attractively priced
Supporting Valuation Data
Moolec Science SA Ordinary Shares (MLEC) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 0.25%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Moolec Science SA Ordinary Shares (MLEC) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 3 register as strengths (avg 9.3/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, Price/Book. Valuation metrics including Price/Sales (0.01), Price/Book (1.07) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 948.00%.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -174.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -174.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 948.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MLEC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MLEC's Price-to-Sales ratio of 0.01x sits near its historical average of 0.01x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 53% below its historical high of 0.02x set in Mar 2026, and -5% above its historical low of 0.01x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Moolec Science SA Ordinary Shares (MLEC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Moolec Science SA Ordinary Shares is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 8M with 948% growth year-over-year.
Key Findings
Revenue growing at 948% YoY, reaching 8M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -3.74 indicates a conservative balance sheet with 767,919 in cash.
Free cash flow is -30M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Moolec Science SA Ordinary Shares maintain 948%+ revenue growth, or will competition slow it down?
Debt management: total debt of 247M is significantly higher than cash (767,919). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Moolec Science SA Ordinary Shares.
Bottom Line
Moolec Science SA Ordinary Shares is a high-conviction growth story with revenue accelerating at 948% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Moolec Science SA Ordinary Shares(MLEC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.